Melanoma drug Zelboraf (vemurafenib, Daiichi Sankyo Co. Ltd. and Roche AG) and lung cancer drug Xalkori (crizotinib, Pfizer Inc.) proved incorporating a companion diagnostic early in clinical development can save time and money: Both drugs advanced from Phase I to FDA approval in five years. (See BioWorld Insight, Sept. 6, 2011.)